Dette blev tilskrevet pioglitazons virkning, idet det mindsker den maternelle hyperinsulinæmi, samt øget insulinresistens, som forekommer under graviditet, hvorved de tilgængelige metaboliske substrater til fostrets vækst reduceres.
This was attributable to the action of pioglitazone in diminishing the maternal hyperinsulinaemia and increased insulin resistance that occurs during pregnancy thereby reducing the availability of metabolic substrates for foetal growth.